-
BIOMARKER-DRIVEN TREATMENT PATTERNS AND GUIDELINE CONCORDANCE IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): REAL-WORLD EVIDENCE FROM NORSTELLALINQ CLAIMS AND EHR DATA
Aug 11, 2026, 17:16 PM -
METRELEPTIN EVIDENCE ACROSS CLINICALLY MEANINGFUL HEALTH-STATE TRANSITIONS IN GENERALIZED LIPODYSTROPHY: A MARKOV-BASED MCDA APPROACH
Aug 11, 2026, 17:16 PM -
COMPARISON OF CASE-MIX GROUP AND ICD-10-CA-BASED APPROACHES FOR ADVERSE EVENT COST ESTIMATION IN CANADA
Aug 11, 2026, 17:16 PM -
BEYOND COST-EFFECTIVENESS: ESTIMATING THE SOCIAL VALUE OF PALBOCICLIB OVER ITS LIFECYCLE
Aug 11, 2026, 17:16 PM -
ADDRESSING THE TIMING OF OUT-OF-POCKET MEDICINE COSTS: EARLY FINDINGS FROM A NATIONAL PILOT IN FINLAND
Aug 11, 2026, 17:16 PM -
PREPARING FOR EU-LEVEL HTA OF MEDICAL DEVICES: IMPLICATIONS FOR THE FIRST JCA DEVICE ASSESSMENTS IN 2026
Aug 11, 2026, 17:16 PM -
ESTIMATING A UK EQ-5D-Y-3L VALUE SET USING A STAKEHOLDER-INFORMED PROTOCOL FOR A HEALTH VALUATION STUDY
Aug 11, 2026, 17:16 PM -
UNLOCKING REAL-WORLD EVIDENCE THROUGH DATA LINKAGE: OUTCOMES OF CONTEMPORARY GLUCOSE-LOWERING THERAPIES IN OLDER ADULTS IN IRELAND
Aug 11, 2026, 17:16 PM -
DYNAMIC CIRCADIAN-ADJUSTED DPYD PHENOTYPING FOR FLUOROPYRIMIDINE THERAPY: AN IN SILICO COST-EFFECTIVENESS ANALYSIS FOR PRECISION ONCOLOGY
Aug 11, 2026, 17:16 PM -
INCORPORATING REAL WORLD EVIDENCE (RWE) INTO NICE TECHNOLOGY APPRAISALS: A CASE STUDY OF TA975 (TISAGENLECLEUCEL FOR RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKAEMIA)
Aug 11, 2026, 17:16 PM -
TRENDS AND BURDEN OF HEART VALVE DISEASE IN KOREA: A NATIONAL CLAIMS DATA ANALYSIS
Aug 11, 2026, 17:16 PM -
ANNUAL DIRECT MEDICAL COST OF MYOCARDIAL INFARCTION IN PATIENTS WITH TYPE 2 DIABETES IN TURKIYE: A PUBLIC PAYER MICRO-COSTING ANALYSIS
Aug 11, 2026, 17:16 PM -
STRUCTURAL PATIENT SAFETY FAILURES IN NON-MEDICAL AESTHETIC SETTINGS: EVIDENCE FROM A NATIONWIDE DERMAL FILLER INSPECTION PROGRAM IN SWITZERLAND TO INFORM RISK-BASED REGULATORY POLICY
Aug 11, 2026, 17:16 PM -
A BUDGET IMPACT ANALYSIS OF REFLUXSTOP FOR THE TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASE IN GERMANY
Aug 11, 2026, 17:16 PM -
IS THE CLINICAL ADDED VALUE A RELEVANT CRITERION FOR ECONOMIC EVALUATION ELIGIBILITY IN FRANCE? INSIGHTS FROM CEESP APPRAISALS (2014-2026)
Aug 11, 2026, 17:16 PM -
COST-UTILITY ANALYSIS OF REMOTE ISCHEMIC CONDITIONING FOR ACUTE MODERATE ISCHEMIC STROKE BASED ON THE RICAMIS TRIAL
Aug 11, 2026, 17:16 PM -
MATCHING-ADJUSTED INDIRECT COMPARISON: ROZANOLIXIZUMAB VERSUS NIPOCALIMAB IN GENERALIZED MYASTHENIA GRAVIS
Aug 11, 2026, 17:16 PM -
A CONFIGURATION-DRIVEN RAG EVALUATION FRAMEWORK FOR HEALTH ECONOMICS AND OUTCOMES RESEARCH (HEOR)
Aug 11, 2026, 17:16 PM -
VACTS: A PRAGMATIC VALUE-BASED ECONOMIC ARCHITECTURE FOR REAL-WORLD DECISION MAKING
Aug 11, 2026, 17:16 PM -
UNDERSTANDING CHILD AND PARENT PREFERENCES IN PEDIATRIC INFLAMMATORY BOWEL DISEASE MANAGEMENT
Aug 11, 2026, 17:16 PM
